At IgGenix, our mission is to develop first-in-class therapies for millions of people whose daily lives are limited by allergies. We believe we can truly change the face of allergic disease, empowering people to live life without the constant fear of a life-threatening allergic reaction.
At the intersection of biotechnology and allergy, our team begins with a deep understanding of molecular immunology thanks to our SEQ SIFTER™ antibody discovery platform. We then leverage this unique understanding to develop products intended to provide faster and more sustained clinical responses. Our first lead development candidate in food allergy, a first-in-class antibody, takes a revolutionary approach to directly address allergic disease by blocking the allergic cascade.
Latest News
The IgGenix Platform
Our single cell RNA-sequencing-based discovery platform, SEQ SIFTER™, captures extremely rare human B cells that produce IgE antibodies directly from human blood. Through our unique technology, IgGenix isolates and re- engineers fully human, high affinity, allergen-specific IgG antibodies designed to block and prevent the allergic cascade. By targeting common immunodominant allergens and their most immunodominant epitopes across the patient population, we intend to treat allergic pediatric and adult patients alike.
Pipeline
IgGenix is currently conducting research as part of an Institutional Review Board-approved observational study to create allergy therapeutics. IgGenix has discovered IgE antibodies and is conducting research across allergic diseases.
Several programs are currently in the IgGenix pipeline targeting both food and environmental allergies. Additional platform opportunities exist in other disease areas in which IgE and/or rare cells play an important role.
Food Allergies
Environmental Allergies
Publications
Immunocomplexed Antigen Capture and Identification by Native Top-Down Mass Spectrometry
Journal of the American Society for Mass Spectrometry
Evolution Toward Chip-Based Arrays in the Laboratory Diagnosis of Human Allergic Disease
The Journal of Allergy and Clinical Immunology: In Practice
IgGenix: Engineering Antibodies to Fight Food Allergies
Nature Biotechnology
Abstracts
Presented at FOCIS 2023 Annual Meeting
Treating Peanut Allergy with an IgG4 Monoclonal Antibody-based Approach
Presented at EAACI 2023 Congress
Deconstructing the Human IgE Response in Peanut Allergy
Presented at WAO 2023 Symposium
The IgGenix Team
Management
Chief Executive Officer
Chief Scientific Officer
Chief Technical Officer
Scientific Co-Founders
Stanford University; Chan Zuckerberg Biohub
Kari Nadeau, M.D., Ph.D., F.A.A.A.A.I.
Stanford University
Board of Directors
IgGenix
Khosla Ventures
Alexandria Real Estate Equities, Inc. / Alexandria Venture Investments
Stanford University; Chan Zuckerberg Biohub
Prosperity Capital Management
Scientific Advisory Board
Kari Nadeau, M.D., Ph.D., F.A.A.A.A.I.
Stanford University
Hans Oettgen, M.D., Ph.D.
Harvard Medical School
Stephen Quake, D. Phil.
Stanford University; Chan Zuckerberg Biohub
Scott Smith, M.D., Ph.D.
Vanderbilt University
Dale Umetsu, M.D., Ph.D.
Stanford University; University of California, San Francisco
Jim Wells, Ph.D.
University of California, San Francisco
Investors
Careers
We are a small, innovative and passionate team working in a fast-paced environment at the forefront of allergy immunology. We have exciting opportunities for enthusiastic, self-motivated, and detail-oriented individuals to join the growing team at IgGenix. IgGenix offers competitive compensation, comprehensive benefits, equity, and the opportunity for growth.
Scroll through our list of open positions and apply today!
For more information contact us at HR@IgGenix.com.
Current Job Opportunities
IgGenix is a rapidly growing company. Please check back for available positions soon.
Contact
IgGenix, Inc
681 Gateway Blvd., Floor 4
South San Francisco, CA 94080
650-491-9626
info@IgGenix.com